Effects of DPP-4 inhibitors on cardiovascular risk in type 2 diabetic patients / 中华内分泌代谢杂志

ABSTRACT

As diabetes is a major independent risk factor for the development of cardiovascular disease (CVD), cardiovascular safety should be taken into account when it refers to the treatment of type 2 diabetes (T2DM). Relevant evidence has suggested that dipeptidyl peptidase 4 (DPP-4) inhibitors could regulate cardiovascular system function by multiple various mechanisms,with inconsistent results among clinical trials. Meta-analysis showed that DPP-4 inhibitors could significantly reduce the CVD risk factors. However,the results from three large scale cardiovascular safety studies were of non-inferiority results. The baseline elder age of participants with longer duration of diabetes and more risk factors of CVD could contribute to the non-inferiority cardiovascular outcomes of DPP-4 inhibitors. Recent clinical trials further indicated that alogliptin and sitagliptin could attenuate atherosclerosis progression of patients with T2DM,which would bring new implications for the clinical use of DPP-4 inhibitors. More research should be designed to further explore the specific mechanism.